Iqvia Holdings Inc (N:IQV)
Business Focus: Biotechnology & Medical Research
Apr 15, 2024 04:15 pm ET
IQVIA to Announce First-Quarter 2024 Results on May 2, 2024
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2024 financial results before the market opens on Thursday, May 2, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Apr 08, 2024 04:01 pm ET
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud
IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.
Mar 06, 2024 04:15 pm ET
IQVIA CFO Ron Bruehlman to Speak at Barclays Annual Global Healthcare Conference on March 13, 2024
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m. ET.
Feb 26, 2024 08:00 am ET
IQVIA Publishes its 2023 Environmental, Social and Governance Report
IQVIA™ (NYSE:IQV), has published its 2023 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.
Feb 23, 2024 09:00 am ET
Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
Global biopharma R&D productivity rebounded in 2023 with higher composite success rates enabled by industry-wide and regulator adoption of data and technology driven innovation, including novel trial design, optimized biomarker use, and digital and decentralized trial methodologies. This rebound occurred while clinical trial starts and funding returned to pre-pandemic levels, according to the new report, “Global Trends in R&D 2024: Activity, Productivity, and Enablers,” released by the IQVIA Institute for Human Data Science.
Feb 21, 2024 04:15 pm ET
IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 29, 2024 at 9:30 a.m. ET.
Feb 14, 2024 07:00 am ET
IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2023.
Feb 06, 2024 09:00 am ET
IQVIA Named to Fortune® World's Most Admired Companies™ List, Ranked #1 in Its Sector for the Third Consecutive Year
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to the Fortune® World's Most Admired Companies™ list for the seventh consecutive year.
Jan 24, 2024 04:15 pm ET
IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jan 17, 2024 06:00 am ET
Global Medicine Spending to Reach $2.3 Trillion by 2028 as More Patients Get Access to Better Therapies, Says IQVIA Institute Report
Global spending and demand for medicines will increase over the next five years to approximately $2.3 trillion by 2028 as more patients get access to new and better medicines, according to a new report from the IQVIA Institute for Human Data Science titled, “The Global Use of Medicines 2024 – Outlook through 2028.”
Nov 29, 2023 08:30 am ET
IQVIA Digital Enablement Named PM360 Trailblazer 2023 Supplier/Vendor of the Year
IQVIA™ (NYSE:IQV), a leading global provider of data, analytics, technology solutions and services to the life sciences industry, today announced that IQVIA Digital Enablement has been named a PM360 Trailblazer 2023 Company of the Year in the Supplier/Vendor category.
Nov 21, 2023 04:15 pm ET
IQVIA CFO Ron Bruehlman to Speak at Evercore HealthCONx Conference on November 29, 2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Evercore Annual HealthCONx Conference in Miami on Wednesday, November 29, 2023 at 10:50 a.m. ET.
Nov 17, 2023 09:23 am ET
IQVIA Announces Upsizing of its Allocation of New Term B Loans
IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Borrower”), allocated a new term B loan due 2031 of approximately $1,500 million (the “New Term Loan B”), which was upsized due to lender demand.
Nov 15, 2023 09:11 am ET
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes
IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), priced an offering of $1,250 million in aggregate principal amount of senior secured notes due 2029 (the “Notes”), which was upsized due to strong demand. Substantially concurrently with the closing of this offering, the Borrower intends to amend its senior secured credit facilities (the “Credit Agreement Amendment”) to provide for a new term B loan due 2031 of approximately $1,250 million (the “New Term Loan B”).
Nov 14, 2023 09:07 am ET
IQVIA Announces Offering of Senior Secured Notes
IQVIA Holdings Inc. (NYSE:IQV) (the “Company”) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer” or “Borrower”), intends to raise $500,000,000 through an offering of senior secured notes due 2029 (the “Notes”).
Nov 06, 2023 08:00 am ET
IQVIA’s Christina Mack Named 2023 PharmaVoice 100 Honoree
IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, announced that Dr. Christina Mack, chief scientific officer, has been named to the 2023 PharmaVoice 100 list.
Nov 01, 2023 07:00 am ET
IQVIA Reports Third-Quarter 2023 Results
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2023.
Oct 23, 2023 08:00 am ET
IQVIA to Provide Sanofi Its Orchestrated Customer Engagement (OCE) Platform in Africa & Middle East
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announced that Sanofi will use the
Oct 11, 2023 07:30 am ET
IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission
IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission.
Oct 09, 2023 04:15 pm ET
IQVIA to Announce Third-Quarter 2023 Results on November 1, 2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Oct 05, 2023 08:00 am ET
Patient Organizations Gave $22 Billion in Grants for Research, Patient Services, and Access to Care Over the Last 5 Years, Says IQVIA Institute for Human Data Science
Patient organizations play a vital role in the U.S. healthcare system, according to a new report from the IQVIA Institute for Human Data Science, Supporting Patients through Research Collaboration: Interactions Between Patient Organizations and Life Sciences Companies. Over the past five years, patient organizations have contributed $22.2 billion in grants to support patient services, research, and access to care.
Oct 03, 2023 08:00 am ET
IQVIA Builds on its Strategic Collaboration with argenx to Provide Safety Systems and Services
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a strategic collaboration with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and so
Sep 25, 2023 08:01 pm ET
IQVIA Appoints Richard Staub III President of Research & Development Solutions
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit.
Sep 12, 2023 08:30 am ET
IQVIA Named a Leader in Pharmacovigilance Solutions in IDC MarketScape Report
IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, has been named a Leader in the IDC Marketscape Worldwide Life Science R&D Pharmacovigilance Solutions 2022
Sep 05, 2023 08:30 am ET
IQVIA CFO Ron Bruehlman to Speak at Baird Global Healthcare Conference on September 13, 2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Baird 2023 Global Healthcare Conference in New York City on Wednesday, September 13, 2023 at 10:50 a.m. ET.
Sep 01, 2023 08:30 am ET
IQVIA CEO Ari Bousbib to Speak at Morgan Stanley Annual Global Healthcare Conference on September 12, 2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Morgan Stanley Annual Global Healthcare Conference in New York City on Tuesday, September 12, 2023 at 11:30 a.m. ET.
Aug 01, 2023 07:00 am ET
IQVIA Reports Second-Quarter 2023 Results
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2023.
Jul 06, 2023 04:15 pm ET
IQVIA to Announce Second-Quarter 2023 Results on August 1, 2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2023 financial results before the market opens on Tuesday, August 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jul 05, 2023 11:00 am ET
IQVIA and the NBA Selected for Abbott’s UNIVANTS of Healthcare Excellence Award
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been recognized along with the National Basketball Association and partners at Harvard, Columbia and BioReference Laboratories for its work in supporting the league with the 2020 NBA Bubb
Jun 29, 2023 08:30 am ET
IQVIA selected ‘Leader’ in Everest Group Life Sciences Sales and Marketing Operations PEAK Matrix® Assessment 2023
IQVIA™ (NYSE:IQV), a global provider of data, analytics, technology solutions and services to the life sciences industry, was recognized as the highest scoring provider in the ‘Leader’ category of Everest Group’s Life Sciences Sales and Marketing Operations PEAK Assessment.
Jun 27, 2023 09:30 am ET
IQVIA Wins Prestigious “Best AI-based Solution for Healthcare” Award in 2023 Artificial Intelligence Breakthrough Awards
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, today announced that it has been selected as winner of the “Best AI-based Solution for Healthcare” award in the sixth annual
Jun 26, 2023 08:30 am ET
IQVIA Launches RIM Smart Labeling to Deliver Intelligence-Driven Approach for Global Label Management
IQVIA™ (NYSE:IQV) today announced the launch of IQVIA RIM Smart Labeling, a comprehensive labeling solution for the life sciences industry that provides an intelligence-driven approach for more efficient and compliant global label management. Through this
May 25, 2023 02:00 am ET
IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthe
May 24, 2023 08:00 am ET
Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science
Global research and development activity in oncology remained at historically high levels in 2022, up 22% from 2018, and the global number of patients treated with approved medicines increased at an average of 5% annually over the same period, according to a new report from the IQVIA Institute for Human Data Science on
May 18, 2023 04:38 pm ET
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes
IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 (the “Senior Secured Notes”) and $500,000,000 in aggregate principal amount of senior notes due 2030 (the “Senior Notes” and, together with the Senior Secured Notes, the “Notes”). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer’s
May 18, 2023 08:25 am ET
IQVIA Announces Offering of Senior Secured Notes and Senior Notes
IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the “Notes”).
May 11, 2023 11:00 am ET
IQVIA Celebrates Sheetal Telang, Winner of Healthcare Businesswoman's Association Rising Star Award
IQVIA (NYSE:IQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA).
May 02, 2023 08:00 am ET
Use of Medicines in the U.S. Continued to Grow in 2022 while Patient Out-of-Pocket Costs Remain Low, Says IQVIA Institute
The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilization, which is now back to pre-pandemic levels, and the entry of new medicines into the market. Balancing these drivers of growth, was a lack of net price increases for branded drugs and patient out-of-pocket costs per retail prescription remaining under $10. This is according to a new report from the IQVIATM Institute for Human Data Science, The Use of Medicines in the U.S. 2023: Usage and
Apr 27, 2023 07:00 am ET
IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2023.
Apr 20, 2023 11:00 am ET
IQVIA Named a Leader in Everest Group Life Sciences Customer Experience Platforms PEAK Matrix® Assessment 2023
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement (OCE) platform.
Apr 06, 2023 04:15 pm ET
IQVIA to Announce First-Quarter 2023 Results on April 27, 2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Mar 14, 2023 08:00 am ET
Global Clinical Trial Activity Remained Resilient in 2022 Despite The Continued Pandemic, Says IQVIA Institute
In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Trends in R&D 2023: Activity, Productivity and Enablers, released by the IQVIA™ Institute for Human Data Science. The report also found that
Mar 01, 2023 04:15 pm ET
IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.
Feb 23, 2023 11:00 am ET
IQVIA Publishes its 2022 Environmental, Social and Governance Report
IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.
Feb 10, 2023 07:00 am ET
IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2022.
Feb 09, 2023 12:00 pm ET
IQVIA Named to FORTUNE’s 2023 List of “World’s Most Admired Companies,” Ranked #1 in Its Category for the Second Consecutive Year
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for the sixth consecutive year.
Jan 31, 2023 08:30 am ET
IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial & Clinical Solutions in China
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the first life sciences industry collaboration with Alibaba Cloud in China. IQVIA and Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, will be providing solutions hosted in Mainland China leveraging Salesforce on Alibaba Cloud. This will enable customers with a path to begin using or extending their investments on the best-in-class platform for engaging with their custom
Jan 25, 2023 04:15 pm ET
IQVIA to Announce Fourth-Quarter and Full-Year 2022 Results on February 10, 2023
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jan 18, 2023 08:00 am ET
Global Market for Medicines to Rise to $1.9 Trillion by 2027, says Report from IQVIA Institute
The total spending and global demand for medicines will increase over the next five years to approximately $1.9 trillion by 2027, according to a new report titled Global Use of Medicines 2023 – Outlook through 2027 from the IQVIA Institute for Human Data Science.
Jan 03, 2023 10:05 am ET
Lasso announces a significant step forward in healthcare marketing measurement
The healthcare marketing and analytics leader expands their Measurement Suite to include unprecedented audience and campaign insights.
Dec 28, 2022 07:30 am ET
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
IQVIA was selected because of its dedicated gastrointestinal team and depth of experience in running cell-therapy clinical trials.
Nov 10, 2022 11:00 am ET
IQVIA and Clalit Health Services partner to advance research by launching the first Prime Site in Israel
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a long-term collaboration with Clalit, the largest health services organization in Israel, to launch the first Prime Site in the country.
Oct 26, 2022 07:00 am ET
IQVIA Reports Third-Quarter 2022 Results
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2022.
Oct 24, 2022 04:15 pm ET
IQVIA CFO Ron Bruehlman to Speak at Credit Suisse Annual Healthcare Conference on November 8, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Credit Suisse Annual Healthcare Conference in Rancho Palos Verdes on Tuesday, November 8, 2022 at 12:10 p.m. ET (9:10 a.m. PT).
Oct 06, 2022 08:15 am ET
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.
Oct 03, 2022 04:15 pm ET
IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2022 financial results before the market opens on Wednesday, October 26, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Sep 28, 2022 10:00 am ET
IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation.
Sep 07, 2022 08:15 am ET
New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced new evidence that decentralized clinical trials (DCT) deliver measurable benefits for patients, sites and sponsors.
Sep 02, 2022 08:15 am ET
IQVIA CEO Ari Bousbib to Speak at Baird Global Healthcare Conference on September 14, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2022 Global Healthcare Conference in New York City on Wednesday, September 14, 2022 at 2:35 p.m. ET.
Sep 01, 2022 04:15 pm ET
IQVIA CFO Ron Bruehlman to Speak at Morgan Stanley Annual Global Healthcare Conference on September 13, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Global Healthcare Conference in New York City on Tuesday, September 13, 2022 at 11:10 a.m. ET.
Aug 15, 2022 07:30 am ET
IQVIA Wins Snowflake’s “Marketplace Healthcare and Life Sciences Partner of the Year” Award
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced it has been named the 2022 Marketplace Healthcare and Life Sciences Partner of the Year by Snowflake, the Data Cloud company.
Jul 21, 2022 07:00 am ET
IQVIA Reports Second-Quarter 2022 Results
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2022.
Jul 07, 2022 04:15 pm ET
IQVIA to Announce Second-Quarter 2022 Results on July 21, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2022 financial results before the market opens on Thursday, July 21, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jul 06, 2022 07:30 am ET
IQVIA Recognized as a Leader in Life Science Sales and Marketing IT Outsourcing Services
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced the company has been named a Leader in the IDC MarketScape: Worldwide Life Science Sales and Marketing IT Outsourcing Services 2022 Vendor Assessment (doc #US41808017, March 2022). The report
Jun 07, 2022 08:00 am ET
IQVIA Appoints Dr. Christina Mack Chief Scientific Officer of Real World Solutions
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company’s Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA.
Jun 01, 2022 08:00 am ET
Global Oncology R&D Surges While Cancer Care Disruptions Ease, Says IQVIA Institute for Human Data Science
Global research and development in oncology continues to surge with historically high levels of trial starts in 2021, up 56% from 2016. Also, a record 30 novel active substances launched globally last year, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2022. While disruptions in cancer care are easing, more new patients were presenting to community oncologists with metastatic disease in several tumors during 2020 and 2021 due to delays in diagnosis and screenings.
May 25, 2022 04:43 pm ET
IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Jefferies Healthcare Conference in New York City on Friday, June 10, 2022 at 11:30 a.m. ET.
Apr 27, 2022 07:00 am ET
IQVIA Reports First-Quarter 2022 Results
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2022.
Apr 21, 2022 08:00 am ET
Spending on U.S. Medicines Rose 12% in 2021 Due to COVID-19 Vaccines and Therapies, Says IQVIA Institute for Human Data Science
Spending on medicines in the United States, at estimated net manufacturer prices, reached $407 billion in 2021, up 12% over 2020, as COVID-19 vaccines and therapeutics became widely available and added $29 billion in related spending. That’s according to a new U.S. Medicines Trends 2022 Report, released today by the IQVIA Institute for Human Data Science. In the same year, the non-COVID medicines market grew more slowly, at 5%, from the growing impact of biosimilars, which increased significantly, offsetting increased use of branded medicines.
Apr 12, 2022 04:15 pm ET
IQVIA to Announce First-Quarter 2022 Results on April 27, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2022 financial results before the market opens on Wednesday, April 27, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Mar 30, 2022 06:00 pm ET
IQVIA Selected to Support EMA’s DARWIN EU® Coordination Centre Initiative
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that the European Medicines Agency (EMA) has awarded a contract to Erasmus University Medical Center Rotterdam to provide analytics services to the DARWIN EU® Coordination Centre which IQVIA was selected to support. IQVIA will also work alongside the University of Oxford, Synapse, The Hyve, and Odysseus Data Services.
Mar 15, 2022 06:05 pm ET
IQVIA Launches OCE+ To Deliver Enhanced AI-Driven Customer Engagement
IQVIA™ (NYSE:IQV) today announced the launch of OCE+, the first of several new advancements to its leading life science customer engagement platform. OCE+ adds IQVIA’s Next Best recommendation engine – a daily workflow tool providing AI-driven recommendations for engaging healthcare professionals (HCP) – to its Orchestrated Customer Engagement (OCE) platform, providing enhanced HCP experiences, improved productivity, and increased ROI.
Mar 14, 2022 09:00 am ET
IQVIA Appoints Costa Panagos President of Research & Development Solutions (R&DS)
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities.
Mar 03, 2022 04:15 pm ET
IQVIA CFO to Speak at Barclays Global Healthcare Conference on March 16, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 16, 2022 at 1:35 p.m. ET.
Mar 01, 2022 08:00 am ET
IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod alfa fcab) by argenx SE
IQVIA (NYSE:IQV) announced an agreement today with argenx SE. The multi-year contract covers a unique collaboration for the development of new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis in adult patients who have a specific antibody receptor.
Feb 24, 2022 08:00 am ET
IQVIA Named Top CRO in 2021 WCG CenterWatch Independent Survey
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry was named the top CRO in Overall Reputation by clinical trial sites around the world in the 2021 WCG CenterWatch Global Site Relationship Benchmark Survey Report.
Feb 22, 2022 08:00 am ET
IQVIA Releases 2021 Environmental, Social, and Governance (ESG) Report
IQVIA (NYSE:IQV) today published its 2021 Environmental, Social, and Governance (ESG) Report. The annual report highlights the significant efforts the company has made in advancing healthcare globally, increasing the diversity and engagement of its workforce, and reducing its global environmental footprint.
Feb 15, 2022 07:00 am ET
IQVIA Reports Fourth-Quarter and Full-Year 2021 Results; Raises Full-Year 2022 Profit Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2021.
Feb 10, 2022 04:15 pm ET
IQVIA CFO Ron Bruehlman to Speak at Citi’s 2022 Virtual Healthcare Conference on February 24, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 11:00 a.m. ET.
Feb 10, 2022 08:00 am ET
Pharma R&D Pipeline and New Product Launches Reach Record Levels in 2021 According to New IQVIA Institute for Human Data Science Report
Biopharmaceutical R&D continued at a record-breaking pace in 2021 despite the COVID-19 pandemic, according to a new report, “Global Trends in R&D – Overview Through 2021,” by the IQVIA Institute for Human Data Science. The data show 5,500 new planned clinical trial starts occurred last year, a 14% increase over 2020.
Feb 02, 2022 08:40 am ET
IQVIA Named to FORTUNE’s 2022 List of “World’s Most Admired Companies,” Ranked #1 in Health Care: Pharmacy and Other Services
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for the fifth consecutive year. This year, IQVIA secured the first place ranking in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks regarding efficient use of corporate assets, management quality, effectiveness in conducting business globally, and long-term investment value.
Feb 01, 2022 04:15 pm ET
IQVIA to Announce Fourth-Quarter and Full-Year 2021 Results on February 15, 2022
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) will announce its fourth-quarter and full-year 2021 financial results before the market opens on Tuesday, February 15, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jan 26, 2022 05:01 pm ET
Sheila A. Stamps Joins IQVIA Board of Directors
IQVIA (NYSE:IQV) today announced the appointment of Sheila A. Stamps to its board of directors, effective today. Ms. Stamps brings more than four decades of strategic, governance and operational management experience. During her extensive career she held senior executive leadership positions in both public and private sector organizations, most recently as a senior investment advisor to the Comptroller of the State of New York for the NYS Common Retirement Fund and as Commissioner on the board of the New York State Insurance Fund, the state’s largest provider of worker’s compensation insurance
Jan 24, 2022 05:00 pm ET
Leslie Wims Morris Joins IQVIA Board of Directors
IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced the appointment of Leslie Wims Morris to its board of directors, effective today.
Dec 09, 2021 08:00 am ET
Global Medicine Spending to Reach $1.8 Trillion in 2026, Including Spending on COVID-19 Vaccines, According to Study by the IQVIA Institute for Human Data Science
Global spending on medicines — based on invoice price levels — is expected to grow at 3-6% CAGR through 2026 to reach about $1.8 trillion by 2026, including spending on COVID-19 vaccines and novel therapeutics, according to a new report, The Global Spending and Usage of Medicines, released by the IQVIA™ Institute for Human Data Science.
Dec 06, 2021 07:00 am ET
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of...
Dec 02, 2021 08:00 am ET
IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Services Unit
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, is launching new Research Nursing and Phlebotomy services. These new services offer patients participating in clinical trials access to a global network of high-quality, credentialed professionals that provide compassionate protocol-required care within their own homes.
Dec 01, 2021 08:00 am ET
IQVIA Recognized as a Leader in BPO Solutions for Pharmaceutical Sales and Marketing
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, was judged a Leader by International Data Corporation (IDC) in its 2021 MarketScapeTM focused on the Worldwide Life Science Sales and Marketing Business Process Outsourcing (BPO) Pharma space. IDC reached its conclusion based on in-depth and rigorous analysis utilized in its MarketScape research.
Nov 19, 2021 10:38 am ET
IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engagement Platform
IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the launch of Grants and Funding Management, new module within the Orchestrated Customer Eng
Nov 18, 2021 08:00 am ET
IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engagement Platform
IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the launch of Grants and Funding Management, new module within the Orchestrated Customer Eng
Oct 21, 2021 07:00 am ET
IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2021.
Oct 12, 2021 08:00 am ET
IQVIA to Announce Third-Quarter 2021 Results on October 21, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2021 financial results before the market opens on Thursday, October 21, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Oct 07, 2021 11:00 am ET
IQVIA to Host Financial Analyst and Investor Conference on November 16, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will host an Analyst and Investor Conference in New York City on Tuesday, November 16, 2021. Management will provide an update on the business, with presentations starting at 10:00 a.m. ET and concluding at approximately 12:30 p.m. ET. Registration is required to attend the event.
Oct 06, 2021 08:00 am ET
IQVIA Announces Opening of New Q2 Solutions Innovation Laboratories in North Carolina, Creating New Jobs and Expanded Capabilities
IQVIA™, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the opening of a state-of-the-art, 160,000-square-foot lab facility for its Q2 Solutions subsidiary. These custom-designed laboratory spaces will be known as Q2 Solutions Innovation Laboratories and are located on the new IQVIA Innovation Park Campus in the heart of the dynamic Research Triangle Park in North Carolina. Through a collaboration with the North Carolina Department of Commerce and the Economic Development
Sep 30, 2021 08:00 am ET
Polpharma Selects IQVIA's Orchestrated Customer Engagement Platform to Improve Salesforce Productivity
IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Polpharma Group BV, a leading Pharmaceutical Company in Rx and OTC medications, has selected IQVIA’s Orchestrated Customer Engagement (OCE) platform to deploy in 12 countries in Central and Eastern Europe, including Poland and Russia.
Sep 13, 2021 04:15 pm ET
IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmacovigilance services and medical information in preparation for potential regulato
Sep 08, 2021 08:00 am ET
IQVIA Collaborates with HealthCore to Advance Clinical Research Using Real-World Data
IQVIA™ (NYSE: IQV) announces its strategic collaboration with HealthCore, Inc., a leading real world research organization in the United States, to advance real world evidence (RWE) studies with increased quality and efficiency. RWE studies incorporate innovative scientific methods with dynamic data from sources such as electronic medical records, pharmacy and medical claims, laboratory and genomics records, and patient-reported outcomes.
Sep 02, 2021 04:15 pm ET
IQVIA CFO, Ron Bruehlman, to Speak at the Baird 2021 Global Healthcare Conference on September 14, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at the Baird 2021 Global Healthcare Conference on Tuesday, September 14, 2021 at 12:15 p.m. EDT.
Sep 01, 2021 08:00 am ET
IQVIA Launches New A.I.-Powered MI Contact Center For Life Sciences
IQVIA™ (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced it has added new AI-powered technologies to enhance its existing Medical Information (MI) Contact Center services.
Jul 27, 2021 07:00 am ET
IQVIA Reports Second-Quarter 2021 Results and Raises Full-Year 2021 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2021.
Jul 22, 2021 08:00 am ET
Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute
Digital health tools are increasingly having a positive impact on health outcomes. Some are becoming integral parts of mainstream medicine, according to findings released today by the IQVIA Institute for Human Data Science in a new report, Digital Health Trends 2021: Innovation, Evidence, Regulation, and Adoption.
Jul 13, 2021 04:15 pm ET
IQVIA to Announce Second-Quarter 2021 Results on July 27, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2021 financial results before the market opens on Tuesday, July 27, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jun 24, 2021 04:15 pm ET
IQVIA Launches the Clinical Data Analytics Suite (CDAS) to Enable Smarter, Faster Clinical Trials
IQVIA™ (NYSE: IQV) today introduced Clinical Data Analytics Suite (CDAS), a new SaaS-based clinical data analytics platform that combines structured and unstructured data from clinical trials into a single, standardized setting for easier access and use. This produces a scalable repository, that helps meet regulatory require
Jun 14, 2021 08:00 am ET
Q² Solutions Announces Significant Expansion of Laboratory Operations in Scotland, UK
Q2 Solutions, a leading global clinical trial laboratory services organization and a wholly owned subsidiary of IQVIA, has announced the expansion of its laboratory and operational capabilities at its Alba Campus in Livingston, Scotland. This expansion of central labs, genomics, flow cytometry, and translational science laboratory services will support new growth areas for biopharma and pharma clients around the world and drive better patient outcomes.
Jun 08, 2021 08:00 am ET
Q2 Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials
Q2 Solutions, a wholly-owned subsidiary of IQVIA and a leading clinical trial laboratory services organization, today announced a transformative collaboration with Tasso Inc., a pioneer in clinical-grade, at-home, patient-centered blood testing, to develop diagnostic tests used in decentralized (virtual) clinical trials. These new laboratory-developed tests will use Tasso’s devices, enabling patients to collect their own blood using a virtually painless process from anywhere at any time.
Jun 03, 2021 04:30 pm ET
Global Oncology Innovation Continues Despite Pandemic; Global R&D Pipeline Reached 3,500 New Drugs in 2020, up 75% from 2015, Says New Report from the IQVIA Institute for Human Data Science
Despite the substantial impact of the COVID-19 pandemic on patient care during 2020, the scientific advances in oncology continued, with 3,500 new drugs in the pipeline in 2020, up 75 percent since 2015. Oncologists worldwide report caseloads that are 26 to 51 percent lower than pre-pandemic levels, resulting in delays in necessary treatments. Despite this, the surge in innovative cancer medicines continued, as reflected in clinical trial activity, the robust pipeline of new treatments in development, and the increased use of available therapeutics by more patients.
May 20, 2021 04:15 pm ET
IQVIA CFO, Ron Bruehlman, to Speak at the William Blair Growth Stock Conference on June 2, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at the William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 10:20 a.m. EDT.
May 19, 2021 08:00 am ET
Pharma R&D Activity Surges Even Without COVID-19, Says Report from the IQVIA Institute for Human Data Science
Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology, according to a new research report Global Trends in R&D: Overview Through 2020 released by the IQVIA™ Institute for Human Data Science.
May 10, 2021 08:00 am ET
U.S. District Court Issues Favorable Decision for IQVIA Against Veeva
IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (NYSE:VEEV). The Court ruled on IQVIA’s motion for sanctions, finding Veeva engaged in massive destruction of evidence, engaged in a cover-up of its wrong-doing, and repeatedly lied about its actions. The court sanctioned Veeva five separate times in the decision to punish Veeva for its violations of rules in the litigation,
May 03, 2021 08:00 am ET
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug
IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021. AZSTARYS is the first and only product containing a dexmethylphenidate (d-MPH) oral prodrug for the treatment of attention deficit hyperactivity disorder (ADHD) symptoms in patients aged six years and older.
Apr 29, 2021 08:00 am ET
Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study
Global spending on medicines — using invoice price levels — is expected to grow at 3-6 percent CAGR through 2025 to reach about $1.6 trillion by 2025, excluding spending of COVID-19 vaccines, according to a new research report The Global Spending and Usage of Medicines released by the IQVIA™ Institute for Human Data Science. The total cumulative spending on COVID-19 vaccines through 2025 is projected to be $157 billion, largely focused on the initial wave of vaccinations to be completed by 2022. In subsequent years, booster shots are expected to be required on a biannual basis as the du
Apr 28, 2021 08:00 am ET
IQVIA Announces Connected Intelligence™
IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced Connected Intelligence™, its innovative approach to enabling life sciences customers to discover powerful new insights, drive smarter decision-making, and get treatments to patients faster.
Apr 22, 2021 07:00 am ET
IQVIA Reports First-Quarter Results; Raises Full-Year 2021 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2021.
Apr 06, 2021 01:00 pm ET
IQVIA to Announce First-Quarter 2021 Results on April 22, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2021 financial results before the market opens on Thursday, April 22, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Apr 01, 2021 07:00 am ET
IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced the acquisition of the 40 percent minority share of Q2 Solutions from Quest Diagnostics (NYSE: DGX), the world leader in diagnostic information services, for $760 million, resulting in 100 percent ownership by IQVIA. The transaction has been financed through cash on hand and is not expected to impact IQVIA’s target net leverage ratio.
Mar 09, 2021 08:00 am ET
IQVIA Virtual Trial Solutions Used in More than 60 Trials
IQVIA™ (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials. Many of these trials, launched in 2020 as virtual and patient-centric solutions, are providing business continuity measures to sponsors during the global pandemic. This
Mar 08, 2021 08:00 am ET
IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials
IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the Phase 3 COVID-19 vaccine clinical trials.
Mar 02, 2021 04:15 pm ET
IQVIA to Participate in the Barclays Global Healthcare Conference on March 09, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on Tuesday, March 09, 2021 at 3:00 p.m. EST.
Feb 17, 2021 04:27 pm ET
IQVIA Announces Pricing of Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €1,450,000,000 in aggregate principal amount of senior notes, consisting of €550,000,000 in aggregate principal amount of senior notes due 2026 (the “2026 Notes”) and €900,000,000 in aggregate principal amount of senior notes due 2029 (the “2029 Notes” and, together with the 2026 Notes, the “Notes”). The proceeds from the Notes offering will be used to redeem all of the Issuer’s outstanding 3.250% senior notes due 2025, including the payment of premiums in
Feb 16, 2021 03:26 am ET
IQVIA Announces Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise €1,450,000,000 in gross proceeds (equivalent to approximately $1,761,000,000) through an offering of senior notes due 2026 and senior notes due 2029 (collectively, the “Notes”). IQVIA also announced that the Issuer intends to deliver a notice of redemption with respect to its outstanding 3.250% senior notes due 2025 (the “3.250% Notes”).
Feb 11, 2021 08:00 am ET
IQVIA’s Orchestrated Customer Engagement (OCE) Solution Selected by 140 Life Sciences Companies in Nearly 90 Countries
IQVIA™ (NYSE:IQV) today announced that 140 life science companies in nearly 90 countries have selected Orchestrated Customer Engagement (OCE) as their customer engagement solution. This milestone reflects the growing demand within the market for IQVIA’s commercial technology to meet the evolving needs of life science companies.
Feb 10, 2021 07:00 am ET
IQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance
Fourth-Quarter 2020 Operating Results
Revenue for the fourth quarter of $3,298 million increased 13.9 percent on a reported basis and 12.2 percent at constant currency, compared to the fourth quarter of 2019. Technology & Analytics Solutions (TAS) revenue of $1,425 million grew 17.4 percent on a reported basis and 15.1 percent at constant currency. Research & Development Solutions (R&DS) revenue of $1,684 million grew 14.5 percent on a reported basis and 13.2 percent at constant currency. Excluding the impact of pass throughs, R&DS revenue increased 12.3 percent year-over-year on a
Feb 04, 2021 08:00 am ET
IQVIA Recognized as Leading eCOA/ePRO Provider in Latest 2020 ISR eCOA/ePRO Market Report
IQVIA™ (NYSE: IQV) today announced that it has been recognized as a top performer by survey respondents in Industry Standard Research’s eCOA/ePRO Market Dynamics and Service Provider Performance (4th Edition) report for overall performance, capabilities, cost, system flexibility and support, system/device integration, and validation and patient compliance. Survey respondents also recognized IQVIA as the No. 1 electronic Clinical Outcome Assessment (eCOA) provider in usability.
Feb 01, 2021 08:00 am ET
IQVIA Named to FORTUNE’s 2021 List of “World’s Most Admired Companies”
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA has received this distinction every year, following the merger between IMS Health and Quintiles in 2016. IQVIA is recognized in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks regarding efficient use of corporate assets, management quality, effectiveness in conducting business globally and long-term investment value.
Jan 26, 2021 04:15 pm ET
IQVIA to Announce Fourth-Quarter and Full-Year 2020 Results on February 10, 2021
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its fourth-quarter and full-year 2020 financial results before the market opens on Wednesday, February 10, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jan 05, 2021 08:00 am ET
Laboratoires Théa Selects IQVIA OCE and OneKey to Accelerate Its Global Digital Transformation
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Laboratoires Théa, the leading independent eye care group in Europe, has selected IQVIA Technologies’
Dec 21, 2020 07:30 am ET
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution
Q2 Solutions, a leading global clinical trial laboratory services organization, resulting from an IQVIA and Quest Diagnostics joint venture, today announced a partnership with Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine. Q2 Solutions will offer its customers the immunoSEQ® Assay, Adaptive’s next-generation sequencing (NGS) based immunosequencing solution, which is used to quantify adaptive immune receptors at high-throughput, leveraging the company’s new immunosequencing kit. Q2 Solutions will also offer immunoSEQ®
Dec 17, 2020 08:00 am ET
Prescription Opioid Use in the U.S. has Declined by 60% from 2011 Peak, According to New Report from the IQVIA™ Institute for Human Data Science
Total national prescription opioid use has declined by 60% from the peak volume in 2011 after another year of double-digit decline that is expected in 2020, according to the latest report from the IQVIA™ Institute for Human Data Science, Prescription Opioid Trends in the United States: Measuring and Understanding Progress in the Opioid Crisis.
Dec 16, 2020 08:00 am ET
IQVIA and Servier Collaborate to Reinvent Clinical Development
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a collaboration with Servier, an independent global pharmaceutical company, to reinvent their R&D clinical development processes and support their long-term R&D success.
Dec 07, 2020 08:00 am ET
IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence
IQVIA™ (NYSE: IQV) said today that it is pleased to be a supporter of the Real World Evidence Leadership Forum, a group consisting of senior RWE executives from 18 major pharmaceutical companies. The forum acts as a non-competitive collaboration to understand, discuss and respond to internal and external RWE challenges and opportunities with a single expert voice and the aim of improving outcomes for patients globally.
Nov 02, 2020 08:00 am ET
IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities
IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Zentiva, a leading player in branded generic and OTC medications in the European and CIS markets, is leveraging IQVIA’s Orchestrated Customer Engagement (OCE) platform across 12 major markets. The platform will be key to helping Zentiva address changes in the market and streamline their commercial operations while creating more impactful customer interactions.
Oct 20, 2020 07:00 am ET
IQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2020.
Oct 12, 2020 08:00 am ET
IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project
IQVIA™ (NYSE: IQV), in scientific partnership with the U.S. Food and Drug Administration, will provide agile analytics from IQVIA’s CARE Project COVID-19 registry to support better understanding of how people in the community are affected by exposure to the coronavirus. IQVIA’s research will show what symptoms individuals experience, the length and severity and whether any medications or vitamin supplements they are taking affect the severity of their coronavirus symptoms.
Oct 07, 2020 04:15 pm ET
IQVIA to Announce Third-Quarter Results on October 20, 2020
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its third-quarter financial results before the market opens on Tuesday, October 20, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Oct 06, 2020 08:00 am ET
IQVIA Institute for Human Data Science Study: Biosimilars Reach Inflection Point – On Track to Reduce Drug Costs by $100 Bn Over Next Five Years
Biosimilar medicine availability and use are growing and on track to reduce drug costs by $100 billion over the next five years, according to a new report from the IQVIA Institute for Human Data Science.
Sep 14, 2020 08:10 am ET
IQVIA’s eCOA Solution Receives 2020 Fierce Innovation Award
IQVIA™ (NYSE: IQV) today announced that its electronic Clinical Outcome Assessment (eCOA) solution, an advanced-study build and execution platform that optimizes real-time, direct-from-patient data collection, has been selected as the winner of the Fierce Innovation Awards – Life Sciences Edition 2020 in the Digital Health Solutions category. The Fierce Innovation Awards is a peer-reviewed awards program produced by Questex, the publisher of Fierce Biotech and Fierce Pharma.
Aug 31, 2020 08:58 am ET
IQVIA’s RIM Smart Honored as Gold Stevie® Award Winner in 2020 American Business Awards®
IQVIA™ (NYSE: IQV) was recognized at the 18th Annual American Business Awards®, winning the Gold Stevie® Award for Technical Innovation of the Year. IQVIA also won a Silver Stevie Award for Most Innovative Company of the Year.
Aug 05, 2020 08:00 am ET
IQVIA’s Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards
IQVIA™ (NYSE: IQV) today announced that Nancy Dreyer, chief scientific officer and senior vice president, Real World Solutions, has been awarded PharmaVOICE magazine’s Red Jacket honor after she was recognized multiple times as a PharmaVOICE 100. IQVIA’s Deepa Desai, vice president and head, Quality Management Systems, Quality Assurance, was honored on the 2020 PharmaVOICE 100 List, which identifies the most influential and inspiring leaders within the life sciences industry.
Aug 04, 2020 08:00 am ET
Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science
The vast majority of patients in the United States are experiencing lower out-of-pocket costs for their drugs, paying a smaller share of costs and seeing a downward trend in their costs on average. That’s according to the latest report from The IQVIA™ Institute for Human Data Science, Medicine Spending and Affordability in the U.S.: Understanding Patient Costs for Medicines. The improved affordability for patients is due to changes in health insurance benefit design, a higher use of generics, record low price increases on branded drugs and more patients reaching “catastrophic” coverage
Jul 29, 2020 08:00 am ET
IQVIA Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness
IQVIA™ (NYSE: IQV) today introduced OCE Optimizer, an innovative solution that empowers life sciences companies to plan and refine marketing engagements with healthcare providers (HCPs) on demand. OCE Optimizer extends IQVIA’s
Jul 23, 2020 08:00 am ET
IQVIA Human Data Science Research Collaborative Initiative Waives Data Access Fees for Academic Researchers
IQVIA™ (NYSE: IQV) announced a new Human Data Science Research Collaborative initiative that is waiving licensing and access fees for approved academic researchers around the world to use two IQVIA data technology platforms and analytics from multiple countries to accelerate research addressing challenges and opportunities for health systems in the COVID-19 era.
Jul 22, 2020 07:00 am ET
IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2020.
Jul 21, 2020 06:00 pm ET
Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
Biogen Inc. (Nasdaq: BIIB) announced today the appointment of Michael (Mike) McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020. McDonnell joins Biogen from IQVIA™ (NYSE: IQV), where he is Executive Vice...
Jul 21, 2020 06:00 pm ET
IQVIA Appoints Ron Bruehlman Executive Vice President and interim Chief Financial Officer
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Ron Bruehlman as Executive Vice President and interim Chief Financial Officer, succeeding Mike McDonnell who is leaving the company to become Chief Financial Officer of Biogen Inc.
Jul 20, 2020 08:01 am ET
IQVIA and JDRF Collaborate to Improve Understanding of Type 1 Diabetes Using Real World Data
IQVIA™ (NYSE: IQV) today announced it is joining forces with JDRF, the leading global organization funding type 1 diabetes (T1D) research, to use non-identified patient-level, real world data and analytics to address unmet needs in the diabetes community.
Jul 14, 2020 08:00 am ET
IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine
IQVIA™ (NYSE:IQV) has announced its collaboration with AstraZeneca (LON: AZN) to accelerate development of a potential new vaccine for COVID-19. This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project.
Jul 08, 2020 04:15 pm ET
IQVIA to Announce Second-Quarter Results on July 22, 2020
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its second-quarter financial results before the market opens on Wednesday, July 22, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jul 02, 2020 08:00 am ET
IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada
IQVIA™ (NYSE: IQV) today announced its strategic alliance with LMC Manna Research, the largest network of fully owned and integrated clinical research sites in Canada, to launch IQVIA’s first Prime Site in Canada. This adds to our network of more than 980 Prime and Partner clinical sites globally, which are sites with special designation assuring pharmaceutical and biotech companies their clinical trials will take place in premier investigative research centers with recognized professionals and with infrastructure focused on innovation and research development for patients.
Jun 10, 2020 05:58 pm ET
IQVIA Announces Pricing of Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €711,000,000 in aggregate principal amount of senior notes due 2028 (the “Notes”). The proceeds from the Notes offering will be used to redeem all of the Issuer’s outstanding 3.500% senior notes due 2024, including the payment of premiums in respect thereof, to repay a portion of the existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering.
Jun 03, 2020 08:00 am ET
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Improves Oncology’s Standard of Care with Genomics Technology Collaboration
Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its partnership with Thermo Fisher Scientific to use the Ion Torrent Genexus System, the first fully integrated, next-generation sequencing (NGS) platform, to deliver clinical trial lab results economically with unprecedented speed.
May 21, 2020 08:00 am ET
IQVIA Launches the First Solution to Address the Unique Business and Compliance Needs of Healthcare Professionals as Part of Its OCE Suite
IQVIA™ (NYSE: IQV) today announced the launch of HCP/O Engagement Management, the industry’s first end-to-end, orchestrated healthcare professional/organization (HCP/O) solution that enables the planning, management, contracting, and payment of HCP/Os globally.
May 20, 2020 08:00 am ET
IQVIA Collaborates with Australian Medical Research Institute on COVID-19 Study to Support Frontline Healthcare Workers
IQVIA™ (NYSE: IQV) today announced that the Walter and Eliza Hall Institute of Medical Research, a leading biomedical research organization in Australia, has selected IQVIA to manage COVID SHIELD, a Phase II/III ra
Apr 29, 2020 09:20 am ET
IQVIA Joins UK Government Collaboration to Provide Single Research Platform to Speed Development of New COVID-19 Treatments
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the ACCORD-2 collaboration, which will fast-track development of new treatments for COVID-19. IQVIA will provide a single research platform across the United Kingdom to facilitate multiple clinical trials regardless of sponsor. This strategic alliance will examine the effectiveness of repurposed medicines, potential new drugs, and unlicensed therapies for treating COVID-19 patients.
Apr 28, 2020 07:00 am ET
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2020.
Apr 07, 2020 09:28 am ET
IQVIA Launches Broad, Open COVID-19 Registry Platform to Advance Understanding, Collaboration, and Research
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced the launch of its COVID Active Research Experience (CARE) Project at helpstopcovid19.com. The IQVIA CARE Project is an opt-in registry available to anyone – to advance understanding of COVID-19 through shared information about disease prevalence, symptom progression, and treatmen
Apr 06, 2020 07:00 pm ET
IQVIA Launches First Technology-Enabled COVID-19 Trial Matching Solution within the U.S. to Accelerate Treatment and Vaccine Development
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects.
Apr 03, 2020 07:02 am ET
ObvioHealth Launches Virtual COVID-19 Symptoms & Immune Response Registry
SINGAPORE and NEW YORK, April 3, 2020 /PRNewswire/ -- ObvioHealth, a digital research company, announces the launch of a registry to monitor COVID-19 prevalence, symptoms and immune response in the United States over the coming 12 months.
Apr 02, 2020 08:29 pm ET
IQVIA Provides Update on Business Conditions in Light of COVID-19 and Provides Revised First-quarter 2020 Guidance; IQVIA will announce first-quarter results and update full-year 2020 guidance on Apri
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today updated its first-quarter 2020 guidance and provided a business update in light of the global COVID-19 crisis.
Mar 24, 2020 08:00 am ET
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Collaborates with University of Texas Medical Branch to Help Accelerate Development of COVID-19 Vaccines
Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its collaboration with the University of Texas Medical Branch (UTMB) to develop a novel assay for COVID-19 (SARS-CoV-2) tests, an essential tool for rapid development of a Coronavirus vaccine. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.
Feb 20, 2020 08:49 am ET
IQVIA Launches Avacare Clinical Research Network to Increase Patients’ Clinical and Research Options
IQVIA™ (NYSE: IQV), a leader in human data science, today announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites. Avacare’s unique analytical tools help sites in Avacare’s network match patients to clinical trials faster and more effectively.
Feb 13, 2020 04:41 pm ET
IQVIA Announces Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that it has agreed to purchase an aggregate of 1,000,000 shares (the “Shares”) of its common stock in a private transaction from certain of its existing stockholders (the “Repurchase”). In addition to the Repurchase, affiliates of TPG Global, LLC, investment funds associated with Bain Capital Investors, LLC and CPP Investment Board Private Holdings Inc. informed IQVIA that they have sold 4,000,000 shares of IQVIA’s common stock pursuant to Rule 144 under the Securities Act of 1933, as amended, for a total of 5,000,000 shares.
Feb 12, 2020 07:00 am ET
IQVIA Reports Fourth-Quarter and Full-Year 2019 Results Issues First-Quarter and Full-Year 2020 Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter and year ended December 31, 2019.
Feb 03, 2020 08:00 am ET
IQVIA Launches FluSTAR Mobile App to Help Consumers Manage Their Health During Flu and Cold Season
IQVIA™ (NYSE: IQV) today announced the launch of the FluSTAR mobile application to help consumers understand and track flu and cold severity this winter. IQVIA’s FluStar app uses near real-time updates complied at www.FluSTAR.com, for current illness information for every ZIP code in the country, accessible from any mobile device.
Jan 30, 2020 08:00 am ET
IQVIA’s Breakthrough Natural Language Processing Platform Receives 2019 Fierce Innovation Award
IQVIA™ (NYSE: IQV) announced today that its Linguamatics Natural Language Processing (NLP) platform has been selected as the winner in Questex’s 2019 Fierce Innovation Awards — LifeSciences Edition in the Data Analytics/Business Intelligence category. The Fierce Innovation Awards is a peer-reviewed awards program from the publisher of FierceBiotech and FiercePharma and recognizes IQVIA Linguamatics NLP platform as an industry-leading product.
Jan 29, 2020 04:15 pm ET
IQVIA to Announce Fourth-Quarter and Full-Year 2019 Results and Issue 2020 Guidance on February 12, 2020
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its fourth-quarter and full-year 2019 financial results and issue 2020 guidance before the market opens on Wednesday, February 12, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jan 23, 2020 08:00 am ET
AP-HP, Europe’s Leading Clinical Research Center, and IQVIA Collaborate to Launch the Largest Clinical Investigation Site in Europe
Assistance Publique – Hôpitaux de Paris (AP-HP), Europe's leading clinical research center, joins IQVIA™, the global health technology and human data science company, to launch the Paris Prime Site for clinical trials. This AP-HP partnership represents IQVIA’s second Prime Site within France, as well as the 43rd globally, the 18th within Europe and largest research facility of its kind within that region.
Jan 21, 2020 08:00 am ET
IQVIA Named to FORTUNE’s 2020 List of “World’s Most Admired Companies”
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) has been named to FORTUNE magazine’s “World’s Most Admired Companies” list. IQVIA has received this distinction every year, since its inception, following the merger between IMS Health and Quintiles in 2016. IQVIA is recognized in FORTUNE’s Healthcare: Pharmacy and Other Services category with high marks regarding efficient use of corporate assets, management quality, effectiveness in conducting business globally, and long-term investment value.
Dec 19, 2019 08:00 am ET
AstraZeneca Selects IQVIA OCE to Help Further its Digital Focus
IQVIA™ (NYSE: IQV) today announced that AstraZeneca (LON: AZN) has selected IQVIA Technologies’ Orchestrated Customer Engagement (OCE) platform to further its digital agenda and establish its “Field of the Future.”
Oct 30, 2019 07:00 am ET
IQVIA Reports Third-Quarter 2019 Results
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2019.
Oct 16, 2019 04:15 pm ET
IQVIA to Announce Third-Quarter 2019 Results on October 30, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its third-quarter 2019 financial results before the market opens on Wednesday, October 30, 2019. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Daylight Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Oct 02, 2019 08:00 am ET
IQVIA Launches Orchestrated Patient Engagement
IQVIA™ (NYSE: IQV) today announced the launch of Orchestrated Patient Engagement (OPE), a new cloud-based software as a service (SaaS) solution that helps close the gap between life sciences companies and patients. The OPE SaaS solution is powered by Belong.Life technology to allow life sciences customers to facilitate interactions and gain insights from patients who opt-in
Oct 01, 2019 08:00 am ET
IQVIA Launches IQVIA Consumer Health to Meet the Growing Business Needs of the Retail Health Sector
IQVIA™ (NYSE:IQV) today announced the launch of IQVIA Consumer Health, dedicated to supporting companies to drive innovation, operate more efficiently, optimize expanding product portfolios, and revitalize existing brands. IQVIA Consumer Health applies deep domain expertise, global and local regulatory intelligence, and insights that transform data into actionable strategies. This unique suite of solutions employs advanced technologies to help customers make quick, precise decisions to drive healthcare forward in a highly competitive market.
Sep 18, 2019 08:00 am ET
IQVIA Collaborates with Cancer Researchers to Advance Use of Real World Evidence
IQVIA™ (NYSE:IQV) is proud to announce its collaboration with Friends of Cancer Research in a cross-industry effort to advance acceptance and drive future uses of real world evidence (RWE). This research helps confirm that clinical benefits seen for therapies in clinical trials were consistent with the benefits of those treatments within real world settings. RWE comprises dynamic data including assets such as EMR, hospital, pharmacy, and claims sources, as well as genomics, mobile health, and patient reported outcomes. The project is part of a Friends of Cancer Research initiative that is work
Sep 17, 2019 08:00 am ET
IQVIA MedTech Launches Enhanced EQMS including EU MDR Support
IQVIA™ (NYSE:IQV) today announced the launch of its latest release of the IQVIA SmartSolve® Enterprise Quality Management Solution (EQMS). This marks the world’s first EQMS to provide expanded quality, regulatory, and safety compliance support for the new European Union Medical Device Regulation 2017/745/EU (EU MDR). This includes support for the new Manufacturer Incident
Aug 26, 2019 08:00 am ET
IQVIA Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that it received notice of an unsolicited “mini-tender” offer by TRC Capital Investment Corporation (TRC Capital) to purchase up to one million IQVIA common shares at a price of $148.35 per share in cash. The offering price is 4.42 percent below the closing price per share of IQVIA’s common stock on August 16, 2019, the last trading day before the offer was commenced, and 3.13 percent below the closing price per share of IQVIA’s common stock on August 23, 2019. The offer is for approximately 0.51 percent of the common shares outstanding.
Aug 21, 2019 04:15 pm ET
IQVIA to Participate in Baird 2019 Global Healthcare Conference on September 4, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2019 Global Healthcare Conference in New York, NY on Wednesday, September 4, 2019 at 9:40 a.m. ET.
Aug 15, 2019 08:00 am ET
IQVIA Launches Patient Portal to Transform the Clinical Trial Experience
IQVIA™ (NYSE:IQV) announces its launch of the IQVIA Patient Portal, a global web-based solution built on a leading health cloud platform. This innovative tool enables increases in clinical trial patient recruitment, engagement and retention by ensuring transparency and collaboration before, during, and after a clinical study.
Aug 08, 2019 04:40 pm ET
IQVIA Announces Repurchase of Common Stock
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that it has agreed to purchase an aggregate of 1,000,000 shares (the “Shares”) of its common stock in a private transaction from certain of its existing stockholders (the “Repurchase”). In addition to the Repurchase, affiliates of TPG Global, LLC, investment funds associated with Bain Capital Investors, LLC and CPP Investment Board Private Holdings Inc. informed IQVIA that they have sold 4,000,000 shares of IQVIA’s common stock pursuant to Rule 144 under the Securities Act of 1933, as amended, for a total of 5,000,000 shares.
Aug 05, 2019 08:00 am ET
IQVIA Named Real World Evidence Market Leader
IQVIA™ (NYSE:IQV) today announced that a new Life Science Strategy Group (LSSG) report named IQVIA the market leader in real world data and real world evidence services. One hundred biopharma companies involved in drug development and commercialization participated in this latest LSSG survey. Respondents overwhelmingly chose IQVIA as the thought leader and expert across r
Aug 01, 2019 08:15 am ET
IQVIA’s Cynthia Verst Honored on 2019 PharmaVOICE 100 List
IQVIA™ (NYSE:IQV) today announced that Cynthia Verst, IQVIA’s president, Design and Delivery Innovation, Research & Development Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry.
Jul 31, 2019 10:22 am ET
Spruce Point Capital Management Releases A Strong Sell Research Opinion On Penumbra, Inc. (NYSE: PEN)
NEW YORK, July 31, 2019 /PRNewswire/ -- Report entitled "Sucking Wind" outlines how Penumbra faces 40-55% downside risk to approximately $85.00 to $110.00 per share after accounting for a wave of new competition, deeply misunderstood market share loss, pricing pressure and a contracting valuation premium as growth slows.
Jul 30, 2019 04:10 pm ET
IQVIA Announces Pricing of Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €720,000,000 in aggregate principal amount of senior notes due 2028 (the “Notes”). The net proceeds from the Notes offering, together with available cash, will be used to redeem the Issuer’s outstanding 4.875% senior notes due 2023 and to pay fees and expenses related to the Notes offering.
Jul 29, 2019 03:00 am ET
IQVIA Announces Offering of Senior Notes
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $800,000,000 equivalent in gross proceeds through an offering of euro-denominated senior notes due 2028. IQVIA also announced that the Issuer delivered a conditional notice of redemption with respect to its outstanding 4.875% senior notes due 2023 (the “4.875% Notes”).
Jul 24, 2019 07:00 am ET
IQVIA Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / July 24, 2019 / IQVIA Holdings, Inc. (NYSE: IQV) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 24, 2019 at 9:00 AM Eastern Time.
Jul 24, 2019 07:00 am ET
IQVIA Reports Second-Quarter 2019 Results, Raises Full-Year Revenue and Adjusted Diluted EPS Guidance
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2019.
Jul 23, 2019 08:00 am ET
IQVIA Awarded Frost & Sullivan’s Life Sciences Product Leadership Award for Its Advanced Quality Management Technology Solution
IQVIA™ (NYSE:IQV) today announced it has received the Frost & Sullivan’s 2018 Global Enterprise Quality Management Solutions for Life Sciences Product Leadership award. IQVIA Technologies’ SmartSolve®, a best-in-class, integrated enterprise quality management solution (EQMS), was selected for its unique ability to address the needs of life sciences companies in qualit
Jul 22, 2019 08:00 am ET
IQVIA Named to Forbes 2019 List of America’s Best Employers for Women
IQVIA Holdings Inc. (“IQVIA™”) (NYSE: IQV) has been named to the Forbes 2019 list of America’s Best Employers for Women. Forbes joined with market research firm Statista to identify the companies liked most by female employees based on various workplace criteria that included pay equity, diversity, family support, working conditions, and parental leave.
Jul 15, 2019 04:40 pm ET
Martin Marietta Appoints New Member to Board of Directors
Martin Marietta Materials, Inc. (NYSE:MLM) today announced the appointment of Thomas (Tom) H. Pike as an independent member to its Board of Directors, effective July 15, 2019. With Mr. Pike’s appointment, the Martin Marietta Board is comprised of...
Jul 09, 2019 04:15 pm ET
IQVIA to Announce Second-Quarter 2019 Results on July 24, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its second-quarter 2019 financial results before the market opens on Wednesday, July 24, 2019. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Daylight Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at
Jun 25, 2019 08:00 am ET
IQVIA Introduces Patient Centered Endpoints Solution with Transformative eCOA Technology Platform
IQVIA™ (NYSE:IQV) today announced the launch of the Patient Centered Endpoints (PCE) solution, an innovative science and technology-enabled approach that captures quantified evidence of patients’ experiences during clinical trials and real world studies. This disruptive technology enables trial sponsors to better understand the patients’ experiences on various therapies, reduce study implementation timelines, and enhance data transparency.
Jun 17, 2019 08:00 am ET
Chiesi Group Selects IQVIA’s OCE Technology Platform to Develop a Customer Centric Ecosystem across the Organization
IQVIA™
(NYSE:IQV) today announced that Chiesi Farmaceutici, the international
research-focused healthcare Group (Chiesi Group) is leveraging IQVIA
Technologies’
Jun 13, 2019 04:15 pm ET
IQVIA’s OCE Technology Platform Selected by Ferring Pharmaceuticals
IQVIA™
(NYSE:IQV) today announced that Ferring
Pha
Jun 04, 2019 08:00 am ET
IQVIA’s OCE Technology Platform Selected by Zambon to Establish a Global Multichannel Commercial Engagement Model for OTC Business
IQVIA™
(NYSE:IQV) today announced that Zambon,
an Italian multinational pharmaceutical and fine-chemical company, has
selected
May 30, 2019 04:15 pm ET
IQVIA Real World Capabilities and Expertise Support Path to Label Expansion
IQVIA™
(NYSE:IQV) is pleased to have provided support towards the approval from
the U.S. Food and Drug Administration to expand the indications for
IBRANCE® (palbociclib) in combination with an aromatase inhibitor or
fulvestrant to include the treatment of men with hormone
receptor-positive (HR+), human epidermal growth factor receptor
May 30, 2019 08:00 am ET
IQVIA™ Institute for Human Data Science Releases Global Oncology Trends 2019 Study: Record Number of Cancer Drugs Launched in 2018 across 17 Indications
The IQVIA™ Institute for Human Data Science found in its latest report, Global
Oncology Trends 2019: Therapeutics, Clinical Development and Health
System Implications, that in 2018 a record-setting 15 new active
substance (NAS) oncology treatments with 17 indications, including one
tissue-agnostic therapy, launched in the U.S. Those 2018 debuts bring
the total number of new oncology therapeutics launched since 2013 to 57
covering 89 approved indications for 23 different tumor types.
May 28, 2019 08:00 am ET
IQVIA Women Leaders Recognized for Their Outstanding Contributions to the Advancement of Healthcare
IQVIA™
(NYSE:IQV) today announced that three of the company’s women leaders
have received significant awards for their leadership, vision and
strategic abilities to drive disruptive technologies, improve health
outcomes, and advance innovation.
May 23, 2019 04:15 pm ET
IQVIA to Participate in William Blair Growth Stock Conference on June 5, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari
Bousbib, chairman and chief executive officer, will speak at the William
Blair 39th Annual Growth Stock Conference in Chicago, IL on Wednesday,
June 5, 2019 at 10:40 a.m. CT / 11:40 a.m. ET.
May 14, 2019 04:15 pm ET
IQVIA to Host Financial Analyst and Investor Conference on June 18, 2019
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will host an Analyst and
Investor Conference in New York City on Tuesday, June 18, 2019.
Management will provide an update on the business, with presentations
starting at 9:00 a.m. ET and concluding at approximately 1:00 p.m. ET.
Registration is required to attend the event.
May 13, 2019 04:15 pm ET
IQVIA Launches IQVIA MedTech Dedicated to Medical Device and Diagnostics Industry
IQVIA™
(NYSE:IQV) today announced the launch of IQVIA MedTech and its dedicated
industry focused solutions and services for the medical device and in
vitro diagnostics market, and for companies with combination products.
IQVIA MedTech empowers companies to orchestrate operations across their
entire product lifecycle, from concept-to-market
May 09, 2019 08:00 am ET
IQVIA™ Institute for Human Data Science Releases 2019 Medicines Report on U.S. Drug Consumption; U.S. Rx Opioid Volume Declined 17% in 2018 – Largest Single-Year Drop Ever Recorded
The latest report from the IQVIA™ Institute for Human Data Science found
prescription opioid dosage volume — as defined by morphine milligram
equivalents, or MMEs — declined 17 percent in 2018, marking the
single-largest annual drop ever recorded within the U.S. market.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.